Journal of General Internal Medicine

, Volume 29, Issue 1, pp 133–139 | Cite as

No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use

  • Daniel Fuster
  • Debbie M. Cheng
  • Donald Allensworth-Davies
  • Tibor P. Palfai
  • Jeffrey H. Samet
  • Richard Saitz
Original Research

ABSTRACT

BACKGROUND

Marijuana is the most commonly used illicit drug, yet its impact on health and healthcare utilization has not been studied extensively.

METHODS

To assess the cross-sectional association between frequency of marijuana use and healthcare utilization (emergency department and hospitalization) and health (comorbidity, health status), we studied patients in an urban primary care clinic who reported any recent (past 3-month) drug use (marijuana, opioids, cocaine, others) on screening. Frequency of marijuana use in the past 3 months was the main independent variable [daily/ almost daily, less than daily and no use (reference group)]. Outcomes assessed were past 3-month emergency department or hospital utilization, the presence of medical comorbidity (Charlson index ≥ 1), and health status with the EuroQol. We used separate multivariable regression models adjusting for age, sex, tobacco and other substance use.

RESULTS

All 589 participants reported recent drug use: marijuana 84 % (29 % daily, 55 % less than daily), cocaine 25 %, opioid 23 %, other drugs 8 %; 58 % reported exclusive marijuana use. Frequency of marijuana use was not significantly associated with emergency department use {adjusted odds ratio [AOR] 0.67, [95 % confidence interval (CI) 0.36, 1.24] for daily; AOR 0.69 [95 % CI 0.40,1.18] for less than daily versus no use}, hospitalization [AOR 0.79 (95 % CI 0.35, 1.81) for daily; AOR 1.23 (95 % CI 0.63, 2.40) for less than daily versus no use], any comorbidity [AOR 0.62, (95 % CI 0.33, 1.18) for daily; AOR 0.67 (95 % CI 0.38, 1.17) for less than daily versus no use] or health status (adjusted mean EuroQol 69.1, 67.8 and 68.0 for daily, less than daily and none, respectively, global p = 0.78).

CONCLUSIONS

Among adults in primary care who screen positive for any recent illicit or non-medical prescription drug use, we were unable to detect an association between frequency of marijuana use and health, emergency department use, or hospital utilization.

KEY WORDS

marijuana primary care health status health service utilization 

REFERENCES

  1. 1.
    Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ. 2010;340:c1571.PubMedCrossRefGoogle Scholar
  2. 2.
    Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the united states: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the national survey of mental health and wellbeing. Drug Alcohol Depend. 2001;63(2):147–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Hall W. The respiratory risks of cannabis smoking. Addiction. 1998;93(10):1461–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ. 2009;180(8):814–20.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg. 2008;138(3):374–80.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med. 2006;166(13):1359–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Aldington S, Harwood M, Cox B, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J. 2008;31(2):280–6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29(3):318–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Tyurina A, Krupitsky E, Cheng DM, et al. Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers? Drug Alcohol Depend. 2013.Google Scholar
  13. 13.
    Arendt M, Munk-Jorgensen P, Sher L, Jensen SO. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend. 2011;114(2–3):134–9.PubMedGoogle Scholar
  14. 14.
    Looby A, Earleywine M. Negative consequences associated with dependence in daily cannabis users. Subst Abuse Treat Prev Policy. 2007;2:3.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36(10):1447–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.PubMedCrossRefGoogle Scholar
  18. 18.
    Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–88.PubMedCrossRefGoogle Scholar
  19. 19.
    Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy. 2009;20(6):458–66.PubMedCrossRefGoogle Scholar
  20. 20.
    el-Guebaly N, Armstrong SJ, Hodgins DC. Substance abuse and the emergency room: programmatic implications. J Addict Dis. 1998;17(2):21–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Althaus F, Stucki S, Guyot S, et al. Characteristics of highly frequent users of a swiss academic emergency department: a retrospective consecutive case series. Eur J Emerg Med. 2013.Google Scholar
  22. 22.
    Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415–20.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res. 2005;29(3):389–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Walley AY, Paasche-Orlow M, Lee EC, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Burke RE, Donze J, Schnipper JL. Contribution of psychiatric illness and substance abuse to 30-day readmission risk. J Hosp Med. 2013.Google Scholar
  26. 26.
    Palepu A, Horton NJ, Tibbetts N, Dukes K, Meli S, Samet JH. Substance abuse treatment and emergency department utilization among a cohort of HIV-infected persons with alcohol problems. J Subst Abuse Treat. 2003;25(1):37–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Siegal HA, Falck RS, Wang J, Carlson RG, Massimino KP. Emergency department utilization by crack-cocaine smokers in dayton, ohio. Am J Drug Alcohol Abuse. 2006;32(1):55–68.PubMedCrossRefGoogle Scholar
  28. 28.
    Larson MJ, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Emergency department and hospital utilization among alcohol and drug-dependent detoxification patients without primary medical care. Am J Drug Alcohol Abuse. 2006;32(3):435–52.PubMedCrossRefGoogle Scholar
  29. 29.
    French MT, Fang H, Balsa AI. Longitudinal analysis of changes in illicit drug use and health services utilization. Health Serv Res. 2011;46(3):877–99.PubMedCrossRefGoogle Scholar
  30. 30.
    Marshall BD, Grafstein E, Buxton JA, et al. Frequent methamphetamine injection predicts emergency department utilization among street-involved youth. Public Health. 2012;126(1):47–53.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–95.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Kaner EF, Dickinson HO, Beyer F, et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev. 2009;28(3):301–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.PubMedCrossRefGoogle Scholar
  34. 34.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.PubMedCrossRefGoogle Scholar
  36. 36.
    EuroQol--a new facility for the measurement of health-related quality of life. the EuroQol group. Health Policy. 1990;16(3):199–208.Google Scholar
  37. 37.
    Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38(1):115–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Mukamal KJ, Maclure M, Muller JE, Mittleman MA. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 2008;155(3):465–70.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669–78.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2013

Authors and Affiliations

  • Daniel Fuster
    • 1
  • Debbie M. Cheng
    • 1
    • 2
  • Donald Allensworth-Davies
    • 3
  • Tibor P. Palfai
    • 4
  • Jeffrey H. Samet
    • 1
    • 5
  • Richard Saitz
    • 1
    • 6
  1. 1.Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of MedicineBoston Medical Center and Boston University School of MedicineBostonUSA
  2. 2.Department of BiostatisticsBoston University School of Public HealthBostonUSA
  3. 3.School of Health SciencesCleveland State UniversityClevelandUSA
  4. 4.Department of PsychologyBoston UniversityBostonUSA
  5. 5.Department of Community Health SciencesBoston University School of Public HealthBostonUSA
  6. 6.Department of EpidemiologyBoston University School of Public HealthBostonUSA

Personalised recommendations